




The relative strengths and weaknesses of Zyla Life Sciences are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zyla Life Sciences compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 32% points. The greatest weakness of Zyla Life Sciences is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 82% points.

The company's Economic Capital Ratio, given in the ranking table, is 236%, being 28% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	150,238
Cost of Goods Sold	0
Intangible Assets	10,380
Liabilities, Current	28,664
Liabilities, Non-Current	52,790
Other Assets	3,997
Other Compr. Net Income	130
Other Expenses	20,800
Other Liabilities	1,740
Other Net Income	-6,435
Other Revenues	22,830
Property and Equipment	7,801
Research and Development	27,054
Selling, General and Administrative Expense	26,474

Output Variable	Value in 1000 USD
Assets	172,416
Liabilities	83,194
Expenses	74,328
Revenues	22,830
Stockholders Equity	89,222
Net Income	-57,933
Comprehensive Net Income	-57,868
BaseVar	179,666
ECR before LimitedLiability	107%
Economic Capital Ratio	236%